Target intelligence / Profile preview

ATP-sensitive inward rectifier potassium channel 11 (KCNJ11) (Kir6.2)

Target
Kir6.2
Molecular classification
Ion channel, Inward rectifier potassium channel, K_ATP channel subunit
01

Overview

The ATP-sensitive inward rectifier potassium channel 11 (KCNJ11), commonly known as Kir6.2, is a critical protein that forms the pore-conducting subunit of the ATP-sensitive potassium (K_ATP) channel (UniProt: P48549). It functions as a metabolic sensor by coupling the intracellular ATP/ADP ratio to the cell's membrane potential, primarily in pancreatic beta cells (PubMed: 10592334). When glucose levels rise, increased ATP production leads to the closure of Kir6.2, causing membrane depolarization, calcium influx, and subsequent insulin secretion (StatPearls: NBK545253). Mutations in the KCNJ11 gene are linked to various glycemic disorders, including permanent neonatal diabetes and congenital hyperinsulinism (NCBI Gene: 3767). Pharmacologically, Kir6.2 is a major target for sulfonylureas used in the treatment of type 2 diabetes and neonatal diabetes, as well as diazoxide for hyperinsulinemic states (PubMed: 15166301). Understanding its structure and function is vital for developing precision therapies for metabolic diseases.

Other names
KCNJ11Inward rectifier K(+) channel Kir6.2BIRHHF2TNDM3PHHIMODY13
02

Mechanism of action

Drugs typically modulate the K_ATP channel complex, where Kir6.2 forms the pore. Sulfonylureas and meglitinides bind to the associated SUR1 subunit to induce closure of the Kir6.2 pore, leading to membrane depolarization and insulin release (PubMed: 15166301). Conversely, potassium channel openers like diazoxide stabilize the open state of the Kir6.2 pore, causing hyperpolarization and inhibition of insulin secretion (StatPearls: NBK545253).

03

Biological functions

Insulin secretionGlucose homeostasisRegulation of membrane potentialPotassium transportMetabolic sensing
04

Disease associations

Neonatal diabetes mellitusHyperinsulinemic hypoglycemia of infancyType 2 diabetes mellitusMaturity-onset diabetes of the young (MODY13)
05

Safety considerations

HypoglycemiaCardiovascular side effects due to cross-reactivity with Kir6.1/SUR2 isoformsWeight gainSecondary failure of drug efficacy over time
06

Interacting drugs

Glibenclamide

6 more in the full profile.

07

Biomarkers

Blood glucose levelsSerum insulinC-peptideKCNJ11 genetic variants

Beyond the preview

Go deeper on ATP-sensitive inward rectifier potassium channel 11 (KCNJ11) (Kir6.2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATP-sensitive inward rectifier potassium channel 11 (KCNJ11) (Kir6.2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call